Vanguard Group’s iRadimed IRMD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $54.5M | Sell |
560,048
-6,459
| -1% | -$554K | ﹤0.01% | 2116 |
|
|
2025
Q3 | $40.3M | Buy |
566,507
+5,475
| +1% | +$365K | ﹤0.01% | 2262 |
|
|
2025
Q2 | $33.5M | Buy |
561,032
+6,581
| +1% | +$361K | ﹤0.01% | 2309 |
|
|
2025
Q1 | $29.1M | Buy |
554,451
+17,640
| +3% | +$991K | ﹤0.01% | 2334 |
|
|
2024
Q4 | $29.5M | Buy |
536,811
+22,762
| +4% | +$1.2M | ﹤0.01% | 2395 |
|
|
2024
Q3 | $25.9M | Buy |
514,049
+44,966
| +10% | +$2.07M | ﹤0.01% | 2469 |
|
|
2024
Q2 | $20.6M | Buy |
469,083
+42,606
| +10% | +$1.81M | ﹤0.01% | 2556 |
|
|
2024
Q1 | $18.8M | Sell |
426,477
-398
| -0.1% | -$17.6K | ﹤0.01% | 2632 |
|
|
2023
Q4 | $20.3M | Buy |
426,875
+14,724
| +4% | +$619K | ﹤0.01% | 2591 |
|
|
2023
Q3 | $18.3M | Buy |
412,151
+10,932
| +3% | +$508K | ﹤0.01% | 2584 |
|
|
2023
Q2 | $19.2M | Buy |
401,219
+5,813
| +1% | +$262K | ﹤0.01% | 2609 |
|
|
2023
Q1 | $15.6M | Buy |
395,406
+12,535
| +3% | +$456K | ﹤0.01% | 2710 |
|
|
2022
Q4 | $10.8M | Buy |
382,871
+368
| +0.1% | +$10.5K | ﹤0.01% | 2920 |
|
|
2022
Q3 | $11.5M | Buy |
382,503
+3,866
| +1% | +$135K | ﹤0.01% | 2884 |
|
|
2022
Q2 | $12.9M | Buy |
378,637
+39,380
| +12% | +$1.41M | ﹤0.01% | 2849 |
|
|
2022
Q1 | $15.2M | Buy |
339,257
+29,696
| +10% | +$1.37M | ﹤0.01% | 2927 |
|
|
2021
Q4 | $14.3M | Sell |
309,561
-95,876
| -24% | -$3.87M | ﹤0.01% | 3025 |
|
|
2021
Q3 | $13.6M | Sell |
405,437
-84,476
| -17% | -$2.87M | ﹤0.01% | 3073 |
|
|
2021
Q2 | $14.4M | Buy |
489,913
+187,953
| +62% | +$5.18M | ﹤0.01% | 3016 |
|
|
2021
Q1 | $7.78M | Sell |
301,960
-75,066
| -20% | -$1.79M | ﹤0.01% | 3295 |
|
|
2020
Q4 | $8.6M | Buy |
377,026
+28,233
| +8% | +$652K | ﹤0.01% | 3071 |
|
|
2020
Q3 | $7.46M | Sell |
348,793
-5,186
| -1% | -$116K | ﹤0.01% | 2943 |
|
|
2020
Q2 | $8.22M | Sell |
353,979
-23,300
| -6% | -$500K | ﹤0.01% | 2867 |
|
|
2020
Q1 | $8.05M | Buy |
377,279
+90,476
| +32% | +$2.15M | ﹤0.01% | 2710 |
|
|
2019
Q4 | $6.71M | Buy |
286,803
+9,575
| +3% | +$224K | ﹤0.01% | 3057 |
|
|
2019
Q3 | $5.83M | Buy |
277,228
+1,025
| +0.4% | +$20.9K | ﹤0.01% | 3081 |
|
|
2019
Q2 | $5.65M | Buy |
276,203
+6,658
| +2% | +$157K | ﹤0.01% | 3126 |
|
|
2019
Q1 | $7.57M | Buy |
269,545
+7,332
| +3% | +$192K | ﹤0.01% | 2973 |
|
|
2018
Q4 | $6.41M | Buy |
262,213
+11,915
| +5% | +$320K | ﹤0.01% | 2977 |
|
|
2018
Q3 | $9.3M | Buy |
250,298
+41,184
| +20% | +$1.11M | ﹤0.01% | 2954 |
|
|
2018
Q2 | $4.34M | Buy |
209,114
+14,637
| +8% | +$259K | ﹤0.01% | 3255 |
|
|
2018
Q1 | $2.74M | Buy |
194,477
+9,262
| +5% | +$132K | ﹤0.01% | 3352 |
|
|
2017
Q4 | $2.81M | Buy |
185,215
+9,790
| +6% | +$124K | ﹤0.01% | 3316 |
|
|
2017
Q3 | $1.68M | Sell |
175,425
-5,256
| -3% | -$49.8K | ﹤0.01% | 3450 |
|
|
2017
Q2 | $1.55M | Sell |
180,681
-53,165
| -23% | -$454K | ﹤0.01% | 3459 |
|
|
2017
Q1 | $2.08M | Buy |
233,846
+28,199
| +14% | +$261K | ﹤0.01% | 3369 |
|
|
2016
Q4 | $2.28M | Sell |
205,647
-25,606
| -11% | -$276K | ﹤0.01% | 3319 |
|
|
2016
Q3 | $3.93M | Buy |
231,253
+7,152
| +3% | +$132K | ﹤0.01% | 3123 |
|
|
2016
Q2 | $4.88M | Buy |
224,101
+16,888
| +8% | +$304K | ﹤0.01% | 2995 |
|
|
2016
Q1 | $3.97M | Buy |
207,213
+88,106
| +74% | +$1.69M | ﹤0.01% | 3082 |
|
|
2015
Q4 | $3.34M | Buy |
119,107
+15,933
| +15% | +$450K | ﹤0.01% | 3185 |
|
|
2015
Q3 | $2.51M | Buy |
103,174
+78,714
| +322% | +$1.88M | ﹤0.01% | 3271 |
|
|
2015
Q2 | $569K | Buy |
24,460
+8,440
| +53% | +$154K | ﹤0.01% | 3832 |
|
|
2015
Q1 | $244K | Buy |
16,020
+100
| +0.6% | +$1.48K | ﹤0.01% | 3968 |
|
|
2014
Q4 | $205K | Buy |
+15,920
| New | +$137K | ﹤0.01% | 3902 |
|
Other funds holding IRMD
NTCM
CCM
Vanguard Group's IRMD Position: Q4 2025 in Review
Vanguard Group reduced its iRadimed (IRMD) stake by 1.1% in Q4 2025, selling an estimated $554K and leaving 560,048 shares worth $54.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2116.
Vanguard Group first reported a position in IRMD in Q4 2014 and has held it in 45 quarters since. 217 funds tracked by Wall St. Rank hold IRMD as of Q4 2025.
- Vanguard Group held 560,048 shares of iRadimed worth $54.5M as of Q4 2025.
- Vanguard Group sold 6,459 iRadimed shares in Q4 2025, an estimated $554K.
- iRadimed made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2116 holding.
- Vanguard Group first reported a position in iRadimed in Q4 2014 and has held it in 45 quarters since.
- 217 funds tracked by Wall St. Rank held iRadimed as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.